Dr. Maude St-Onge completed her medical studies at Université de Montréal in 2006, specialized in Emergency Medicine at Laval University in 2011, and in Critical Care at the University of Toronto in 2013, and in Clinical Pharmacology and Toxicology at the University of Toronto, in 2016. Dr. St-Onge obtained a Master’s Degree in Public Health in 2004 and a Ph.D. in Medical Sciences in 2015 from the University of Toronto under the supervision of renowned scientists in the field of acute care, such as Dr. Laurie Morrison (scientist in emergency medicine), Dr. David Juurlink (clinician-scientist in toxicology) and Dr. Gorden Rubenfeld (clinician-scientist in critical care medicine). Her Ph.D. aimed at developing international recommendations for the management of calcium channel blocker poisoning and included a systematic review, a retrospective study, an economic study, a survey, and a Delphi.
Since July of 2015, Dr. Maude St-Onge has been the medical director of the Centre antipoison du Québec, works as an intensivist clinician-scientist at the CHU de Québec and as an assistant professor for the Department of Family Medicine and Emergency Medicine, as well as the Laval University Department of Anesthesiology and Critical Care Medicine. Scientist awarded by the FRQS working at the CHU de Québec – Laval University research center for the Population Health and Optimal Health Practice Research (Trauma – Emergency – Critical Care), Dr. St-Onge’s research interests concern acute care toxicology. She is currently studying the factors influencing adherence to the recommendations she developed during her Ph.D. (qualitative study, matched crossover study), evaluating the risks and benefits related to the administration of activated charcoal to poisoned patients (activated CHARcoal in Poisoned Patients – CHARPP: systematic review, retrospective study, survey, validation of a clinical score, pilot study, clinical trial), and working to better understand the continuum of care provided to Indigenous poisoned patients (CARe for Indigenous Poisoned Patients – CARIPP: scoping review, retrospective study, qualitative study). Indeed, activated charcoal is the most often recommended intervention by poison centres and the Indigenous population is the most affected by poisonings.
Canada G1J 1Z4
- Châteauvert, AmélieMaster student
Drug Administration to the Wrong Nursing Home Residents Reported to the Québec Poison Center: A Retrospective StudyJournal Article
J Am Med Dir Assoc, 19 (10), 2018.
Atraumatic (pencil-point) versus conventional needles for lumbar puncture: a clinical practice guidelineJournal Article
BMJ, 361 , 2018.
Phenytoin overdose treated with hemodialysis using a high cut-off dialyzerJournal Article
Hemodial Int, 21 (1), 2017.
BET 3: In septic patients requiring fluid resuscitation can the bedside lung ultrasound be used to assess the pulmonary fluid status?Journal Article
Emerg Med J, 34 (6), 2017.
Experts Consensus Recommendations for the Management of Calcium Channel Blocker Poisoning in AdultsJournal Article
Crit Care Med, 45 (3), 2017.
Impact of Training and practice setting on the physician’s opinion regarding the treatment of calcium blocker poisoning : a survey of emergency physiciansJournal Article
1 (1), 2016.
Provincial survey of health care professionnals involved in the care of poisoned patientsJournal Article
Qual Prim Care, 24 (4), 2016.
Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 1: Silibinin in suspected amatoxin-containing mushroom poisoningJournal Article
Emerg Med J, 33 (1), 2016.
Papadakos P, Gestring M (Ed.): Encyclopedia of trauma care, pp. 1604-1611, Berlin Heidelberg, Springer, 2015, ISBN: 9783642296116.
Using Guidelines: When Is It Appropriate?Journal Article
3 (4), 2015.
- activated CHARcoal in Poisoned Patients (CHARPP): a pilot Randomized Controlled Trial, from 2023-04-01 to 2024-03-31
- Utilisation du charbon activé chez les patients intoxiqués (CHARPP - Use of activated CHARcoal in Poisoned Patients), from 2016-07-01 to 2023-06-30
Recently finished projects
- Transfusion in traumatic brain injury (TSiTBI Trial), from 2016-07-01 to 2021-06-30